

Title (en)
PHARMACEUTICAL FORMULATION CONTAINING A SELENITETRIGLYCERIDE AND A CYTOSTATIC FOR USE IN TREATMENT OF TUMOUR

Title (de)
PHARMAZEUTISCHE FORMULIERUNG MIT EINEM SELENITETRIGLYCERID UND EINEM ZYTOSTATIKUM ZUR VERWENDUNG BEI DER TUMORBEHANDLUNG

Title (fr)
FORMULATION PHARMACEUTIQUE CONTENANT UN SÉLÉNITE TRIGLYCÉRIDE ET UN AGENT CYTOSTATIQUE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UNE TUMEUR

Publication
EP 3856148 A4 20220615 (EN)

Application
EP 19865889 A 20190926

Priority
• PL 42721618 A 20180927
• PL 2019050055 W 20190926

Abstract (en)
[origin: WO2020067910A2] The invention relates to a pharmaceutical formulation having anti- tumour properties containing at least one cytostatic and selenitetriglyceride, preferably selol as a substance enhancing the effect of the cytostatic for use in the treatment of the tumour, wherein at least one cytostatic and selol are encapsulated in the lipid carrier.

IPC 8 full level
A61K 31/33 (2006.01); **A61K 9/127** (2006.01); **A61K 31/357** (2006.01); **A61K 31/375** (2006.01); **A61K 31/513** (2006.01); **A61K 31/704** (2006.01); **A61K 33/04** (2006.01); **A61P 35/00** (2006.01)

CPC (source: EP)
A61K 9/127 (2013.01); **A61K 31/33** (2013.01); **A61K 31/357** (2013.01); **A61K 31/375** (2013.01); **A61K 31/513** (2013.01); **A61K 31/704** (2013.01); **A61K 33/04** (2013.01); **A61P 35/00** (2017.12)

Citation (search report)
• [Y] PL 229503 B1 20180731 - UNIV WARSZAWSKI [PL], et al
• [E] WO 2020050731 A1 20200312 - NARODOWY INST LEKOW W WARSZAWIE [PL], et al
• [YD] RAYANE GANASSIN ET AL: "Nanocapsules for the co-delivery of selol and doxorubicin to breast adenocarcinoma 4T1 cells in vitro", ARTIFICIAL CELLS, NANOMEDICINE, AND BIOTECHNOLOGY, 27 November 2017 (2017-11-27), pages 1 - 11, XP055706047, Retrieved from the Internet <URL:https://www.tandfonline.com/doi/pdf/10.1080/21691401.2017.1408020> [retrieved on 20200617], DOI: 10.1080/21691401.2017.1408020
• [A] DUDKIEWICZ-WILCZYŃSKA JADWIGA ET AL: "Comparison of selected gene expression profiles in sensitive and resistant cancer cells treated with doxorubicin and Selol", WSPÓŁCZESNA ONKOLOGIA, vol. 2, 1 January 2014 (2014-01-01), pages 90 - 94, XP055917752, ISSN: 1428-2526, DOI: 10.5114/wo.2014.40558
• [Y] DUDKIEWICZ-WILCZYŃSKA JADWIGA ET AL: "The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions", PLOS ONE, vol. 11, no. 5, 19 May 2016 (2016-05-19), pages e0155772, XP055461801, DOI: 10.1371/journal.pone.0155772
• [Y] LOPES SILVIA ET AL: "Interaction of 5-Fluorouracil Loaded Nanoparticles with 1,2-Dimyristoyl- sn -glycero-3-phosphocholine Liposomes Used as a Cellular Membrane Model", JOURNAL OF PHYSICAL CHEMISTRY PART B, vol. 116, no. 1, 28 December 2011 (2011-12-28), US, pages 667 - 675, XP055918020, ISSN: 1520-6106, DOI: 10.1021/jp210088n
• [A] GLUZ O. ET AL: "Triple-negative breast cancer-current status and future directions", ANNALS OF ONCOLOGY, vol. 20, no. 12, 1 December 2009 (2009-12-01), NL, pages 1913 - 1927, XP055918026, ISSN: 0923-7534, DOI: 10.1093/annonc/mdp492
• [A] CARMELA FIMOĞNARI ET AL: "Sulforaphane Modulates Cell Cycle and Apoptosis in Transformed and Non-transformed Human T Lymphocytes", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, NEW YORK ACADEMY OF SCIENCES, US, vol. 1010, no. 1, 24 January 2006 (2006-01-24), pages 393 - 398, XP071398685, ISSN: 0077-8923, DOI: 10.1196/ANNALS.1299.072
• See references of WO 2020067910A2

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)
WO 2020067910 A2 20200402; **WO 2020067910 A3 20200514**; EP 3856148 A2 20210804; EP 3856148 A4 20220615; PL 241189 B1 20220822; PL 427216 A1 20200406

DOCDB simple family (application)
PL 2019050055 W 20190926; EP 19865889 A 20190926; PL 42721618 A 20180927